(2S)-(4E)-N-methyl-5-[(5-isopropoxypyridin)-3-yl]-4-penten-2-amine p-hydroxybenzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-(4E)-N-methyl-5-[(5-isopropoxypyridin)-3-yl]-4-penten-2-amine p-hydroxybenzoate
• 英文别名: (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate；(2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate；4-hydroxybenzoic acid;(E,2S)-N-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine
• 化学式: C₇H₆O₃*C₁₄H₂₂N₂O
• 分子量: 372.464
• InChiKey: IRKXQKVFYQCFHO-IDAJZJLDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.97
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  91.7
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (R)-pent-4-en-2-yl 4-methylbenzenesulfonate 在 palladium diacetate 、 三(邻甲基苯基)磷 盐酸 、 水 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲基叔丁基醚 、 N,N-二甲基乙酰胺 、 醋酸异丙酯 、 水 、 丙酮 为溶剂， 反应 4.75h， 生成 (2S)-(4E)-N-methyl-5-[(5-isopropoxypyridin)-3-yl]-4-penten-2-amine p-hydroxybenzoate
  参考文献：
  名称：

  [EN] NEW PROCESS FOR THE PREPARATION OF ARYL SUBSTITUTED OLEFINIC AMINES
  [FR] NOUVEAU PROCÉDÉ POUR LA PRÉPARATION D'AMINES OLÉFINIQUES À SUBSTITUTION ARYLE

  摘要：

  公开号：

  WO2011146009A8

文献信息

• Hydroxybenzoate salts of metanicotine compounds
  申请人：Munoz A. Julio

  公开号：US20060122237A1

  公开（公告）日：2006-06-08

  Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.

  易感或患有中枢神经系统疾病等状况的患者，通过向需要治疗的患者施用氢氧基苯酸盐型的E-甲基烟碱类化合物来进行治疗。形成E-甲基烟碱化合物的氢氧基苯酸盐也可用于纯化E-甲基烟碱化合物，因为氢氧基苯酸盐倾向于结晶出来，留下杂质，如Z-甲基烟碱化合物和双键迁移的化合物在溶液中。如果需要，氢氧基苯酸盐可以转化为自由基（E-甲基烟碱）或其他药学上可接受的盐形式。
• HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS
  申请人：Dull Gary Maurice

  公开号：US20080249142A1

  公开（公告）日：2008-10-09

  Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine compound) or to another pharmaceutically acceptable salt form.

  易感受或患有中枢神经系统疾病等疾病和疾病的患者，通过给需要治疗的患者施用羟基苯甲酸盐型E-甲烟碱类化合物的组合物来治疗。形成羟基苯甲酸盐的E-甲烟碱化合物也有助于纯化E-甲烟碱化合物，因为羟基苯甲酸盐倾向于结晶出来，留下杂质，例如Z-甲烟碱化合物和双键迁移的化合物在溶液中。如有需要，羟基苯甲酸盐可转化为自由碱（E-甲烟碱化合物）或另一种药学上可接受的盐形式。
• Hydroxybenzoate Salts Of Metanicotine Compounds
  申请人：Munoz Julio A.

  公开号：US20090062321A1

  公开（公告）日：2009-03-05

  Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.

  对于易感受或患有中枢神经系统疾病等疾病和疾病的患者，可以通过向需要治疗的患者施用羟基苯甲酸酯盐的E-甲烟碱型化合物来进行治疗。羟基苯甲酸酯盐的形成对于纯化E-甲烟碱化合物也是有用的，因为羟基苯甲酸酯盐往往会结晶出来，留下杂质，例如Z-甲烟碱化合物和双键迁移的化合物。如果需要，羟基苯甲酸酯盐可以转化为自由碱基（E-甲烟碱）或其他药学上可接受的盐形式。
• New Process for the Preparation of Aryl Substituted Olefinic Amines
  申请人：Dull Gary Maurice

  公开号：US20130225827A1

  公开（公告）日：2013-08-29

  An improved process for the preparation of aryl substituted olefinic amines such as (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine and (2S)-(4E)-N-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine and new intermediates used in said process.

  一种改进的方法，用于制备芳基取代的烯丙胺类化合物，例如(2S)-(4E)-N-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺和(2S)-(4E)-N-甲基-5-[3-(5-甲氧基吡啶)基]-4-戊烯-2-胺，以及在该方法中使用的新中间体。
• Polymorph forms of (2S) - (4E) -N-methyl-5- (3-isopropoxypyridin) yl]-4-penten-2-amine for the treatment of central nervous system disorders
  申请人：Targacept, Inc.

  公开号：EP2418201A1

  公开（公告）日：2012-02-15

  Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, and methods for their preparation, pharmaceutical composition containing said polymorph(s) and use, are disclosed. The polymorphs can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.

  本发明公开了(2S)-(4E)-N-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺对羟基苯甲酸盐的多晶型，以及其制备方法、含有所述多晶型的药物组合物和用途。这些多晶型物可用于易患或患有中枢神经系统疾病等病症的患者，以治疗和/或预防此类疾病。